Biogen posts Q2 2026 revenue rise, shares jump 1.8%
Biogen reported second‑quarter 2026 revenue of $2.7 billion, a 3% increase year‑over‑year, driven largely by its growth portfolio which generated $1.06 billion, up 24%.
Adjusted net income fell to $536 million, or $3.60 per share, compared with $803 million a year earlier. The company lowered its full‑year EPS guidance to $12‑$13 per share from $14.25‑$15.25.
Biogen’s stock rose about 1.8% on the day, outperforming the S&P 500’s 0.2% gain. The earnings call was held on July 29, 2026 at 8:30 AM EDT, featuring CEO Christopher Viehbacher, CFO Robin Kramer and Head of Investor Relations Tim Power.
Entities: Banco Latinoamericano de Comercio Exterior · Banco Latinoamericano de Comercio Exterior S.A. · Biogen Inc. · Biogen growth portfolio · BlueLinx · Christopher Viehbacher · Robin Kramer · Taboola.com · Tim Power · growth portfolio
Claims
What the coverage asserts, and how well corroborated each claim is across sources.
- [○ 1 SOURCE] Biogen's growth portfolio generated $1.06 billion in revenue, a 24% increase year‑over‑year. (Biogen earnings release)
- [○ 1 SOURCE] Biogen reported Q2 2026 revenue of $2.7 billion, up 3% year‑over‑year. (Biogen earnings release)
- [● 2 SOURCES] Biogen held its Q2 2026 earnings call on July 29, 2026, with CEO Christopher Viehbacher and CFO Robin Kramer participating. (Biogen earnings call transcript)
- [○ 1 SOURCE] Biogen's shares rose about 1.8% on the day, outperforming the S&P 500's 0.2% gain. (Biogen)
- [○ 1 SOURCE] Biogen updated its full‑year guidance to expect revenue growth at a mid‑single‑digit rate in 2025. (Biogen earnings release)
- [○ 1 SOURCE] Biogen's adjusted net income for Q2 2026 was $536 million, or $3.60 per share, down from $803 million the previous year. (Biogen)
- [○ 1 SOURCE] Biogen lowered its adjusted EPS guidance for the full year to $12‑$13 per share, from $14.25‑$15.25. (Biogen earnings release)
- [○ 1 SOURCE] Biogen's Q2 2026 revenue was $2.7 billion, up 3% year‑over‑year. (Biogen)
- [● 2 SOURCES] Christopher Viehbacher was President, CEO & Director of Biogen during the Q2 2026 earnings call. (Biogen)
- [○ 1 SOURCE] Biogen's growth portfolio generated $1.06 billion in revenue, a 24% year‑over‑year increase. (Biogen)
- [● 2 SOURCES] Robin Kramer was Executive VP & CFO of Biogen during the Q2 2026 earnings call. (Biogen)
- [○ 1 SOURCE] Biogen lowered its full‑year EPS guidance to $12‑$13 per share, from $14.25‑$15.25. (Biogen)